Results 1 to 10 of about 39,316 (219)
Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma [PDF]
Translational Oncology, 2017 Increased levels of the nuclear export protein, exportin 1 (XPO1), were demonstrated in multiple myeloma (MM) patients. Targeting XPO1 with selinexor (the selective inhibitor of nuclear export; SINE compound KPT-330) demonstrates broad antitumor activity
Barbara Muz +4 more
doaj +4 more sources
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]
PLoS ONE, 2013 Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu +6 more
doaj +1 more source
Molecules, 2023 Bortezomib is an inhibitor of proteasomes and an anti-cancer drug. Although bortezomib is considered a safe drug, as confirmed by cytotoxicity assays, recent reports highlighted the possibility of interaction between bortezomib and cellular components ...
Mihaela-Cristina Bunea +2 more
doaj +1 more source
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
Neoplasia: An International Journal for Oncology Research, 2022 The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Melissa K. Bennett +12 more
doaj +1 more source
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. [PDF]
PLoS ONE, 2013 Bortezomib is an antitumor drug that competitively inhibits proteasome beta-1 and beta-5 subunits. While the impact of bortezomib on protein stability is known, the effect of this drug on intracellular peptides has not been previously explored.
Julia S Gelman +7 more
doaj +1 more source
Asian Journal of Oncology, 2022 Objectives Bortezomib vial-sharing is commonly employed to maximize the treatment of patients with multiple myeloma (MM) in resource-limited setting. This strategy minimizes delays in treatment but reduces the dose of bortezomib received by the patient ...
Jeremiah R. Vallente +2 more
doaj +1 more source
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link [PDF]
, 2011 The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing
Fulda, Simone
core +1 more source
Haematologica, 2015 Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking.
Meletios A. Dimopoulos +13 more
doaj +1 more source
Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species [PDF]
, 2013 Background The radiopharmaceutical 131I-metaiodobenzylguanidine (131I-MIBG) is used for the targeted radiotherapy of noradrenaline transporter (NAT)-expressing neuroblastoma.
Babich, J.W. +4 more
core +3 more sources
Characterization of bortezomib-adapted I-45 mesothelioma cells
Molecular Cancer, 2010 Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy.
Peddaboina Chander +5 more
doaj +1 more source